Discriminating evidence – use and misuse of the drug-discrimination test in abuse potential assessment of novel CNS drugs
Open Access
- 17 April 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 39 (7) , 629-651
Abstract
Nonclinical testing to predict the abuse potential of central nervous system (CNS) drug candidates is a mandatory part of the safety pharmacology assessment for medications seeking approval for human use. In the “standard model,” the drug candidate is tested to determine whether its psychoactive effects generalize to the discriminative cue of an abused drug that animals have been trained to recognize. However, CNS drugs with novel pharmacological mechanisms are challenging, and in response, the regulatory agencies have recommended alternative experimental designs. Variant 1: test the drug candidate in a series of drug-discrimination experiments that exemplify the major classes of abused drugs. Variant 2: use the drug candidate as a training cue. Back-test examples from established classes of abused drugs to see if they generalize to the drug candidate’s cue. We critically assessed the pharmacological and translational validity of these protocols. The standard model is underpinned by decades of research and refinement and has the highest degree of translational validity. Question marks exist over the validity of substitution results when the drug candidate has no affinity for known abuse-related targets. Published research does not support the use of either of the alternative models. On the contrary, these models have no pharmacological rationale and, consequently, no translational validity. The review contains a decision tree on the appropriate application of the standard drug-discrimination model, together with recommendations for adapting the test when characterizing the psychoactive properties of drug candidates acting on novel CNS targets.Keywords
This publication has 144 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy ParticipantsClinical Pharmacology & Therapeutics, 2020
- Drug Discrimination: Historical Origins, Important Concepts, and Principles2018
- Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs2016
- Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage CancerArchives of General Psychiatry, 2011
- Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving ratsSynapse, 2000
- Behavioral evidence for the role of noradrenaline in putative anxiolytic and sedative effects of benzodiazepinesPsychopharmacology, 1988
- Midazolam cue in rats: Effects of Ro 15-1788 and picrotoxinPsychopharmacology, 1986
- Discriminative Stimulus Properties of Δ9‐Tetrahydrocannabinol: Mechanistic StudiesThe Journal of Clinical Pharmacology, 1981
- Stimulus effects of ?9-THC and its interaction with naltrexone and catecholamine blockers in ratsPsychopharmacology, 1977